Splash Beverage Group entered a Development and Collaboration Agreement with Lupvindol Biosciences on July 31, 2026. Lupvindol will lead development and FDA regulatory activities for CannEpil®, an animal drug derived from the Company's licensed product. The Company provides milestone funding totaling $1.115 million across six stages, plus a 4% royalty or stock alternative upon Conditional Approval. This strategic partnership advances the commercialization of veterinary pharmaceuticals.
